CEL-SCI Corporation (CVM) gains over 10%
What’s up with CEL-SCI Corporation?
CEL-SCI Corporation (CVM) opened at $15.48, which means the stock is up 10% from yesterday’s closing price of 14.96. Today, the company has a high of $16.52 and a low of $15.06. The stock holds a market cap of $613.00 million which is not impressive since the P/E ratio is -18.75. The company has a 52-week high of $17.80 and a 52-week low of $3.70.
What is P/E ratio?
The price-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of a company’s share price to the company’s earnings per share. The ratio is used for valuing companies and to find out whether they are overvalued or undervalued. CEL-SCI Corporation has a weak.A negative PE ratio means that a stock has negative earnings. In other words, the company was losing money in the past 12 months.
About CEL-SCI Corporation
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.